High-grade gliomas (e.g., H3K27M-DMG, H3G34-DHG) exhibited elevated HLA class I (HLA-A, HLA-B, and HLA-C) expression, facilitating stronger immune recognition, while embryonal tumors (e.g., medulloblastoma, MRT) displayed significantly lower levels, suggesting an immune-cold phenotype with reduced antigen presentation potential. This evidence concerns the gene HLA-A and central nervous system cancer.